MedTrace Logo

Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients

NCT01260974 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2012-07-18

No results posted yet for this study

Summary

The aim of the study is to determine viable use of caspofungin in post-OLTx patients, and to demonstrate in particular the effectiveness, understood as the ability to reduce the incidence of invasive fungal infections, and to assess the ability to reduce the risk and incidence of side effects (toxicity) which may arise in transplant patients treated with other drugs, especially in individuals recognized as high risk (e.g. renal failure).

Conditions

  • Fungemia
  • Mycoses

Interventions

DRUG

Caspofungin

50mg/dd for 21dd, starting within 24h from Liver Transplantation.

Sponsors & Collaborators

Principal Investigators

  • Umberto Cillo, MD · Azienda Ospedaliera Universitaria di Padova

  • Daniele Neri, MD · Azienda Ospedaliera Universitaria di Padova

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01260974 on ClinicalTrials.gov